Recombinant Human Signal transducer CD24(CD24)-Nanoparticle (Active)


Recombinant Human Signal transducer CD24(CD24)-Nanoparticle (Active)



With an increase in covid 19 cases in the present scenario our principal Cusabio has Recombinant Human Signal transducer CD24(CD24)-Nanoparticle. CD24 is a heat-stable antigen that belongs to the group of glycosylphosphatidylinositol (GPI)-anchored cell surface proteins. CD24 was originally thought to be a marker for B cells and is expressed in the early stages of B cell differentiation, while playing an important role in lymphocyte maturation, neurological development, and tissue renewal in biological process. In 2019, a study revealed a significant role for the CD24/Siglec-10 signaling pathway in ovarian and breast cancer tumors, suggesting that CD24 interacts with Siglec-10 (sialic-acid- binding Ig-like lectin10) on macrophages. The binding of CD24 and Siglec-10 could inhibit phagocytosis of tumor cells by macrophages. On the contrary, knockdown of CD24 or Siglec-10 could promote phagocytosis. Therefore, CD24 as the novel immunotherapy target, is a newly discovered "don't eat me" signaling protein, like the popular molecular CD47.

It is CD24, which regulates the body's immune response through a variety of mechanisms, that really works, and it is by virtue of its ability to restrain the cytokine storms that CD24 is being used to treat patients with moderate to severe COVID-19 disease. CD24 targeted drug-CD24 and Fc fusion protein (CD24-Fc) has been used for COVID-19 therapy before EXO-CD24. CD24 has greater potential as a target than IL-6/IL-6R, but the specific clinical benefit of either CD24-Fc or EXO-C24 for COVID-19 continues to require more clinical validation.